Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

Core Insights - OS Therapies, Inc. announced positive results from a Phase 2b trial of its HER2-targeted immunotherapy candidate, OST-HER2, aimed at preventing recurrent lung metastatic osteosarcoma in pediatric patients [1][2] Clinical Trial Results - The primary endpoint of the study, 12-month event-free survival (EFS), showed a statistically significant improvement for OST-HER2-treated patients at 33% compared to 20% for historical controls (p=0.0158) [4] - Interim analysis of overall survival (OS) indicated a strong trend favoring OST-HER2-treated patients, with 1-year survival at 91% versus 80% for historical controls (p=0.07) and 2-year survival at 61% versus 40% (p=0.0576) [3][4] - All patients who met the primary 12-month EFS endpoint remain alive as of the latest follow-up [3] Financial Developments - OS Therapies recently completed a private placement financing, raising approximately $6 million in gross proceeds, which will be allocated for working capital and to support clinical and regulatory milestones for OST-HER2 [4][5] - Following the announcement, OSTX stock experienced a price increase of 7.96%, reaching $4.49 [5]